ZIM Laboratories (NSE:ZIMLAB, BOM:541400) said Portugal's INFARMED has approved its central nervous system drug, dimethyl fumarate 120 mg & 240 mg modified release capsules, according to an Indian bourse filing on Wednesday.
The marketing authorization was granted to ZIM Lab's European subsidiary, SIA ZIM Laboratories. The approval is expected to aid faster clearances in other EU and global markets, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.